1 / 17

POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION

POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION. (EC) No 1234/2008 1 October 2012 CHMP / CVMP Quality Working Party /EMA. Summary. 1. Post approval change management protocol (PACMP) 2. Concepts 3. Variation categories in the EU

renjiro
Download Presentation

POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. POST APPROVAL CHANGE MANAGEMENT PROTOCOLSIN THE EUROPEAN UNION (EC) No 1234/2008 1 October 2012 CHMP / CVMP Quality Working Party /EMA

  2. Summary • 1. Post approval change management protocol (PACMP) • 2. Concepts • 3. Variation categories in the EU • 4. Mechanismforthesubmission and evaluation of a PACMP • 5. The principle of the Change Management Protocol: a 2-step implementation approach • 6. Content of a PACMP: generalities • 7. Content of a PACMP: The Variations Classifications Guideline • 7.1. The Variations Classifications Guideline. Examples • 8. Benefits

  3. 1. Post approval change management protocol (PACMP) • Concept Introduced in EU through Variations Regulation (Commission Regulation (EC) No 1234/2008). • Text that supports the Variations Regulation: The Variations Classifications Guideline (2010/C 17/01) Classification of variations into categories. Details, on the scientific data to be submitted for specific variations and how this data should be documented.

  4. 2. Concepts • A PACMP is a description of specific change(s) that a company would like to implement following marketing authorization and how these would be prepared and verified. • A PACMP applies to all types of medicinal products for human and veterinary use including biotechnological or biological products. Traditional or enhanced (Quality by Design) approach has been used for its development. • AIM: establish a simple, clearer and more flexible legal framework for the handling mentioned variations of medicinal products, while ensuring a high level of protection of public and animal health.

  5. 2. Concepts • Incorporates a science and risk-based approach to evaluate impact of change(s) on product quality in a proactive manner. • A PACMP should not include changes that would in itself result in a line extension. • Each variation should require a separate submission. • Grouping variations are allowed in certain cases, in order to facilitate the review of the variations and reduce the administrative burden JUSTIFICATIONshowing that the changes are related, and that a simultaneous review under a single protocol is meaningful.

  6. 3. Variation categories in the EU • Minor variation of type IA/IAin: variation which has only a minimal impact, or no impact at all, on the quality, safety or efficacy of the medicinal product concerned and does not require prior approval before implementation (“Do and tell” procedure). e.g. variations related to changes in the packaging material not in contact with the finished product, which do not affect the delivery, use, safety or stability of the medicinal product. • Major variation of type II : variation which is not an extension and which may have a significant impact on the quality, safety or efficacy of the medicinal product concerned. e.g. variations related to significant modifications of the summary of product characteristics due in particular to new quality, pre-clinical, clinical or pharmacovigilance findings. Source: The Variations Classifications Guideline (2010/C 17/01) & (EC) No 1234/2008

  7. 3. Variation categories in the EU • Minor variation of type IB: variation which is neither a minor variation of type IA nor a major variation of type II nor an extension and require prior approval before implementation (‘‘tell, wait and do’’ procedure). e.g. Change in batch size (including batch size ranges) of active substance or intermediate More than 10-fold increase compared to the currently approved batch size. Source: The Variations Classifications Guideline (2010/C 17/01) & (EC) No 1234/2008

  8. 3. Variation categories in the EU

  9. 4. Mechanismforthesubmission and evaluation of a PACMP • May be included in an original marketing authorisation application (MAA) or (line) extension application.  the evaluation of a post approval change management protocol will follow the rules of procedure applicable to the actual MAA. Can be modified via a type II (major change) or type IB (minor change) variation. • May be submitted subsequently as a stand alone variation.  the evaluation will follow the rules of procedure applicable for all Quality Type II variations.

  10. 5. The principle of the Change Management Protocol: a 2-step implementation approach Without PACMP With PACMP

  11. 6. Content of a PACMP: generalities • Justification that there is a recognized future need for the specific change within a reasonable timeframe. • A detailed description of the proposed change. • Risk assessment of the impact of the change on product quality. • Discussion on the appropriateness of the approved control strategy to identify and manage these risks. source: EMA/CHMP/CVMP/QWP/586330/2010

  12. 6. Content of a PACMP: generalities • Description of the studies to be performed, the test methods and acceptance criteria that will be used to fully assess the effect of the proposed change on product quality. • A plan for stability studies should be included, if appropriate. • In case that the protocol describes several changes, a justification showing that the changes are related, and that a simultaneous review under a single protocol is meaningful. • For small molecules, a proposed reporting category for step 2 (type IA or IB variation). • For biologics, the approach to be used to demonstrate the comparability of the pre-, and post-change product. (spec’s and extended characterisation studies). The reporting shall always be made as a Type IB variation. Source: EMA/CHMP/CVMP/QWP/586330/2010

  13. 7. Content of a PACMP:The Variations Classifications Guideline • Classification of variations into categories  • Administrative changes • Quality changes • Safety, Efficacy and Pharmacovigilance changes • Specific changes to Plasma Master Files and Vaccine Antigen Master Files • Details, on the scientific data to be submitted for specific variations and how this data should be documented.

  14. 7.1. The Variations Classifications Guideline.Examples A) Administrativechange B) Qualitychange

  15. 8. Benefits • Expedited review and/or inspection at step 2 of PACMP procedure. • Predictability and transparency in terms of requirements and studies needed to implement a change. • Faster implementation, if the pre-determined criteria of the PACMP are met; use of the PACMP could allow an applicant to implement CMC changes and place a product in distribution sooner than without the use of the PACMP procedure.

  16. 9. References • Variations Regulation (Commission Regulation (EC) No 1234/2008) • The Variations Classifications Guideline (2010/C 17/01) • EMA/CHMP/CVMP/QWP/586330/2010 • Experience of Post approval change management protocol in EU. Mats Welin Senior expert Medical Products Agency Uppsala, Sweden. • Post-approval Change Management Protocols Current Status and Next Steps on the Way towards a Global Tool. Dr. Markus Goese Lead EU CMC Regulatory Policy F. Hoffmann-La Roche Ltd, Basel – Switzerland. • EMA/13667/2015

  17. THANK YOU FOR YOUR ATTENTION!!

More Related